Foghorn Therapeutics Inc. expected to post a loss of 33 cents a share - Earnings Preview

Foghorn Therapeutics

03/03/2025 13:33

Foghorn Therapeutics Inc. FHTX.OQ FHTX.O is expected to show a rise in quarterly revenue when it reports  results on March 5 (estimated) for the period ending December 31 2024

The Cambridge Massachusetts-based  company is expected to report a 27.2% increase in revenue to $7.336 million from $5.77 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Foghorn Therapeutics Inc. is for a loss of 33 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Foghorn Therapeutics Inc. is $13.00​, above​ its last closing price of $4.85. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.42
-0.44
-0.31
Beat
29.6
Jun. 30 2024
-0.63
-0.65
-0.45
Beat
31.3
Mar. 31 2024
-0.56
-0.63
-0.59
Beat
6.9​
Dec. 31 2023
-0.94
-0.76
-0.57
Beat
25.3
​​Sep. 30 2023
-0.74
-0.75
-0.34
Beat
54.7
Jun. 30 2023
-0.74
-0.73
-0.70
Beat
4.8​
Mar. 31 2023
-0.68
-0.72
-0.73
Missed
-0.7
Dec. 31 2022
-0.71
-0.62
-0.69
Missed
-11.7

This summary was machine generated March 3 at 13:33 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)